A talin mutant that impairs talin-integrin binding in platelets decelerates αIIbβ3 activation without pathological...

Area of Science:

• Biochemistry
• Molecular Biology
• Hematology

Background:

• Integrin activation is crucial for hemostasis and platelet function.
• Talin1 binding to integrin β cytoplasmic domain sites is a key step in integrin activation.
• Distinct talin1 interactions with integrin β3's membrane-proximal region (MPR) and NPxY motif regulate affinity.

Purpose of the Study:

• To investigate the in vivo functional significance of talin1's distinct interactions with the integrin β3 subunit.
• To determine the role of talin1-MPR and talin1-NPxY interactions in platelet function, thrombosis, and bleeding.

Main Methods:

• Generated knock-in mice expressing talin1 mutants (L325R, W359A) with impaired binding to β3 integrin MPR or NPxY sequence, respectively.
• Assessed platelet function, thrombosis, and bleeding phenotypes in mutant mice.
• Quantified αIIbβ3 integrin activation and talin1 binding affinity biochemically.

Main Results:

• Both talin1(L325R) and talin1(W359A) mice showed protection from experimental thrombosis.
• Talin1(L325R) mice exhibited severe bleeding, unlike talin1(W359A) mice.
• αIIbβ3 activation was completely blocked in talin1(L325R) platelets and reduced by ~50% in talin1(W359A) platelets, with lower binding affinity and slower activation rates.
• Reduced talin1 binding affinity decelerated αIIbβ3 activation, delayed aggregation, and reduced thrombus formation.

Conclusions:

• The interaction between talin1 and the integrin β3 MPR is critical for full αIIbβ3 activation and preventing pathological bleeding.
• Reduced talin1-integrin β3 binding affinity decelerates integrin activation, offering protection from arterial thrombosis without severe bleeding complications.
• Modulating talin-integrin affinity presents a potential therapeutic strategy for thrombotic disorders.